Full-Time

Product Manager 2

Updated on 9/10/2026

Deadline 10/31/26
RELX

RELX

1,001-5,000 employees

Global information analytics and decision tools

Compensation Overview

$90.5k - $190.5k/yr

+ Annual incentive bonus

No H1B Sponsorship

Remote in USA + 1 more

More locations: North Carolina, USA

Remote

Must work East Coast hours.

US Citizenship, US Top Secret Clearance Required

Bachelor's, Master's

Category
Product (1)
Required Skills
Agile
Product Management
Data Analysis

Get referred to RELX

See people who can refer or advise you

Requirements
  • U.S. citizenship is required.
  • Four to six years of product management experience is required.
  • Demonstrated ability to solve complex problems with multiple constraints, use sound judgment to assess risks, and present arguments in a well-structured, data-informed written narrative.
  • Proven ability to engage constructively and collaboratively with engineers, designers, and company leaders.
  • Strong understanding of software development methodologies, including Agile Scrum and Kanban, and experience writing user stories.
  • Physical and/or logical access to criminal justice information is required, including successful completion of an enhanced criminal background check conducted in compliance with the Federal Bureau of Investigation’s Criminal Justice Information System security policy.
  • Candidates and/or employees must be certified by state and local law enforcement to access criminal justice information.
Responsibilities
  • Own one or more law enforcement product features and lead project execution.
  • Own product development plans and represent product features within cross-functional teams.
  • Propose new feature ideas that address customer pain points or needs based on firsthand customer understanding.
  • Prioritize and communicate production customer issues and defects using relevant data for timely resolution.
  • Lead demonstrations for key stakeholders at program milestones.
  • Execute on the product vision.
  • Develop clear go-to-market launch plans in coordination with customer-facing teams.
  • Independently support go-to-market strategy by communicating customer value propositions, requirements, and timelines to stakeholders.
  • Answer sales and customer questions about feature function, pricing, packaging, value proposition, and competitive position.
  • Participate in market and product messaging focused on desired outcomes.
  • Advance prototypes or minimum viable products based on deep understanding of the feature area.
  • Follow the company’s software development lifecycle processes, including Agile and lean methodologies.
  • Capture customer goals and needs using appropriate frameworks and techniques and prioritize those needs for the organization.
  • Interpret market events into actionable intelligence for features and enhancements.
  • Use knowledge of the company technology stack, platforms, and underlying technologies to create new product features.
  • Communicate with technical and data counterparts about development approaches.
  • Learn new technologies to support development efforts.
  • Apply data and technical architecture principles and best practices.
  • Ask effective questions, collect facts from multiple sources, identify and analyze problems, and propose solutions.
  • Manage day-to-day issues and problems without intervention.
  • Encourage cooperation among team members, remove barriers to team performance, help resolve conflict, and facilitate collaboration and discussion across teams.
  • Establish rapport across teams and work effectively with others to complete work.
Desired Qualifications
  • Experience in government or law enforcement industries and/or with public records.
  • Familiarity with the Accurint and Accurint TraX law enforcement products.
  • Education to qualify: Bachelor’s or Master’s degree in a technical subject, such as Computer Science or an Engineering discipline.

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Get referred to RELX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 revenue grew 7%; Legal grew 10%; Risk grew 8%.
  • February 24, 2026 Lexis+ with Protégé launched globally, expanding AI workflow adoption.
  • September 3, 2026 Doctrine closes, targeting one million European legal professionals.

What critics are saying

  • Anthropic and Thomson Reuters compressed legal AI pricing after February 2026 market shock.
  • Harvey and Legora court law schools in 2026, training future buyer cohorts elsewhere.
  • Exhibitions face Middle East event uncertainty through 2026, threatening margins and calendar-dependent cash flows.

What makes RELX unique

  • LexisNexis’ 200 billion-document corpus still beats generic legal AI models.
  • September 3, 2026 Doctrine acquisition deepens RELX’s European legal AI workflow moat.
  • H1 2026 subscriptions supplied 62% of revenue, stabilizing cash generation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

Citybiz
Apr 28th, 2026
RELX to Acquire Legaltech Platform Doctrine in European AI Push

RELX Group has entered into an agreement to acquire French legal technology company Doctrine, a move that would expand its... Read More

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence